Precigen, Inc. (NASDAQ:PGEN) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Steven Harasym - Vice President and Head of Investor Relations

Helen Sabzevari - President and Chief Executive Officer

Harry Thomasian - Chief Financial Officer

Conference Call Participants

Nick Abbott - Wells Fargo Securities, LLC

Jason Butler - JMP Securities, LLC

Jennifer Kim - Cantor Fitzgerald & Co.

Operator

Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Results Conference Call. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.

Steven Harasym

Thank you, operator, and thank you for joining us today. With me are Dr. Helen Sabzevari, President and CEO of Precigen and Harry Thomasian, our CFO. Helen will provide an update on the significant progress we have made across our pipeline programs and highlight our anticipated upcoming milestones. After which Harry will review our second quarter and first half 2022 financial results. Following our prepared remarks, we will open the call to Q&A.

Before we begin, please note that during today's call, we will make various forward-looking statements. Investors are cautioned that such forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those indicated on forward-looking statements. Please read the safe harbor statement contained in this presentation as well as risk factors contained in Precigen's most recent SEC filings for a more complete discussion of the risks and uncertainties.

I would now like to turn the call over to Dr. Sabzevari. Helen?

Helen Sabzevari

Thanks, Steve, and thanks to all of you for joining us today. We are all accurately aware of the seismic shifts that are shaping in new biopharma landscape. The rules of the past for biotech success in terms of access to capital, clinical trials, regulatory pathways, manufacturing, pricing and commercializations are changing. Traditional funding methods have become more challenging and supply chain issues have led to bottlenecks in traditional manufacturing approaches. Clinical trials that relied on centralized product manufacturing to supply products to sites were particularly hard hit, therefore creating the need for a new paradigm.

Biotech companies are basically having to reinvent themselves for these new times. My goal today is for you to leave this call with an understanding of Precigen’s efforts over the last several years that we believe have enabled us to thrive in these uncertain times. Not only that, but we are one of the few companies that have advanced multiple first-in-class clinical platforms and clinical programs in a highly efficient and rapid way during the pandemic.